



## **FierceBiotech names Vivet Therapeutics as one of its 2017 “Fierce 15” Biotech Companies.**

PARIS, France September 28th, 2017, Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one of 2017's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. The announcement was made during the FierceBiotech Drug Development Forum, which took place Tuesday September 26th in Boston, MA.

Vivet Therapeutics is a biotechnology company developing novel gene therapies for rare, inherited metabolic diseases.

*“Vivet Team is honored to be selected as a Fierce 15 company,” said Jean-Philippe COMBAL, CEO of Vivet Therapeutics. “Our world-class team combined with best-in-class science will allow us to develop life-changing treatments for rare inherited metabolic liver disorders while addressing key challenges of gene therapy, including sustained therapeutic gene expression in young patients, adults and immune responses towards the viral vector”*

Vivet Therapeutics is committed to make a significant difference for patients facing rare metabolic diseases. Vivet has a strategic collaboration with Fundación para la Investigación Médica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, University of Navarra, Spain), a leading research organization in the field of Gene Therapy. Vivet also has licensed the use of novel proprietary AAV vector gene therapy technology to treat metabolic diseases and certain patent-protected Anc80 AAV gene therapy vectors from Massachusetts Eye and Ear (MEE), a teaching hospital of Harvard Medical School, Boston. Anc80 is a next-generation gene therapy technology designed to increase gene expression levels in the liver.

*“We will initiate clinical development of our lead product, VTX-801 for Wilson’s Disease, in Q4 2018 and already have 3 additional programs under preclinical development” stated Jean-Philippe Combal. “Our entire team is committed to advancing our programs to generate transformative therapies for patients with high unmet medical needs.”*



The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech's fifteenth annual Fierce 15 selection. A complete [list of "Fierce 15" companies](#) can be found online.

For more information, visit [www.vivet-therapeutics.com](http://www.vivet-therapeutics.com)

**Media & Investor contact:**

Thomas Daniel

Business Development Director

+33 6 68 88 38 60

[info@vivet-therapeutics.com](mailto:info@vivet-therapeutics.com)

**About VTX-801:** VTX-801 is an adeno-associated virus (AAV) containing a gene coding for a functional mini-ATP7B copper transporter, that is intended to restore copper metabolism through liver cell targeting.

**About FierceBiotech:** FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at [www.fiercebiotech.com/signup](http://www.fiercebiotech.com/signup)

<http://www.fiercebiotech.com/special-report/vivet-therapeutics>

**About Vivet Therapeutics:** Vivet Therapeutics is a gene therapy biotech company with headquarters in Paris, France, dedicated to the research, development and future commercialization of gene therapy products for inherited liver disorders with high medical need.